A Nanovaccine Based on Cationic Lentinan Adjuvant Enhances Protective Immunity against H1N1 and H9N2 Influenza Virus Infection
ACS Applied Materials & Interfaces · 28.01.2026 · 18 (3) · 5708-5720
DOI: 10.1021/acsami.5c21405 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, online erschienen am 14.01.2026. Verfasst von Ruihong Yu und 11 weiteren Autor:innen. Beteiligte Einrichtung: College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210095, China. Hauptthemen laut MEDLINE: Influenza A Virus, H1N1 Subtype, Influenza A Virus, H9N2 Subtype, Influenza Vaccines, Lentinan. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: China Association for Science and Technology, Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China.
Abstract (Originalsprache)
Influenza viruses are highly prevalent and continuously evolving respiratory pathogens that pose a significant threat to global public health and the poultry industry. Immunization remains the primary approach to preventing infection and reducing the risk of an influenza pandemic. Nanoparticles not only serve as delivery vehicles for antigens but also enhance antigen-specific immune responses. Polysaccharide nanoparticles not only amplify the immunostimulatory capacity of polysaccharides but also exhibit superior adjuvant effects. In this study, we investigated the effect of cationic Lentinan (CLNT) as an adjuvant for influenza vaccines. CLNT significantly enhanced the production of specific antibodies against influenza antigens (H1N1 and H9N2) and promoted a strong humoral immune response. Compared with the control group, the CLNT group showed 8.49- and 5.23-fold increases in H1N1- and H9N2-specific IgG antibody levels, respectively. CLNT also activated dendritic cells, T cells, and B cells, thus triggering the cellular immune response. In addition, CLNT effectively inhibited the replication of H1N1 and H9N2 viruses in the trachea and lungs, indicating its potent protective immune effect against influenza virus challenge. This study suggests that CLNT enhances both the potency and breadth of immune responses against influenza viruses, presenting it as a promising adjuvant and offering new options for designing next-generation influenza vaccines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210095, China.
- College of Life Sciences, Longyan University, Longyan 364012, China.
- Academy for Advanced Interdisciplinary Studies, Nanjing Agricultural University, Nanjing 210095, China.
ORCID-Profile: Deyun Wang, Zhenguang Liu
Förderung
- China Association for Science and Technology
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
- National Key Research and Development Program
Zitieren
APA
Yu, R., Song, Z., Jiao, L., Wang, Z., Ma, Y., Zhang, Z., Xu, J., He, Y., Deng, Y., Lin, J., Wang, D., & Liu, Z. (2026). A Nanovaccine Based on Cationic Lentinan Adjuvant Enhances Protective Immunity against H1N1 and H9N2 Influenza Virus Infection. ACS Applied Materials & Interfaces, 18(3), 5708-5720. https://doi.org/10.1021/acsami.5c21405
Vancouver
Yu R, Song Z, Jiao L, Wang Z, Ma Y, Zhang Z, et al. A Nanovaccine Based on Cationic Lentinan Adjuvant Enhances Protective Immunity against H1N1 and H9N2 Influenza Virus Infection. ACS Applied Materials & Interfaces. 2026;18(3):5708-5720. doi:10.1021/acsami.5c21405
BibTeX
@article{Yu2026,
author = {Yu, Ruihong and Song, Zuchen and Jiao, Lina and Wang, Zheng and Ma, Yan and Zhang, Zhimin and Xu, Jie and He, Yuying and Deng, Yilin and Lin, Junhao and Wang, Deyun and Liu, Zhenguang},
title = {A Nanovaccine Based on Cationic Lentinan Adjuvant Enhances Protective Immunity against H1N1 and H9N2 Influenza Virus Infection},
journal = {ACS Applied Materials & Interfaces},
year = {2026},
volume = {18},
number = {3},
pages = {5708--5720},
doi = {10.1021/acsami.5c21405}
}
EUVIMED